Valuation: Gilead Sciences, Inc.

Market Cap 167B 146B 135B 124B 235B 16,077B 238B 1,612B 632B 7,865B 626B 612B 27,086B P/E 2026 *
-48x
P/E 2027 * 16.9x
Enterprise Value 176B 154B 143B 131B 248B 16,990B 252B 1,704B 668B 8,311B 662B 647B 28,623B EV / Sales 2026 *
5.78x
EV / Sales 2027 * 5.15x
Free-Float
99.88%
Yield 2026 *
2.44%
Yield 2027 * 2.52%
1 day-0.80%
1 week+2.60%
Current month+5.44%
1 month+7.64%
3 months-3.22%
6 months+6.64%
Current year+8.53%
1 week 129.4
Extreme 129.405
140.61
1 month 123
Extreme 123
140.61
Current year 116.88
Extreme 116.88
157.29
1 year 107.75
Extreme 107.75
157.29
3 years 62.07
Extreme 62.07
157.29
5 years 57.16
Extreme 57.165
157.29
10 years 56.56
Extreme 56.56
157.29
Manager TitleAgeSince
Chief Executive Officer 61 2019-02-28
Director of Finance/CFO 56 2019-10-31
Compliance Officer - 2025-12-17
Director TitleAgeSince
Director/Board Member 58 2016-08-18
Director/Board Member 73 2017-12-31
Director/Board Member 72 2018-05-08
Date Insider Type Main position Quantity % Market Cap.
7/15/26 Sell

Executive/Senior Manager

-3,000 0.0002%
7/15/26 Sell

Chief Financial Officer

-3,000 0.0002%
7/1/26 Sell

Chief Executive Officer

-15,000 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
-0.80%+2.60%+23.09%+68.71% 167B
-2.73%-3.51%+48.62%+152.87% 1,051B
-1.67%-3.18%+52.00%+56.75% 609B
-0.44%+2.14%+33.88%+84.04% 450B
-0.75%-1.46%+28.32%+22.33% 330B
-1.52%-0.95%+33.38%+38.39% 284B
-1.70%-3.54%+20.26%+17.88% 263B
-0.58%+1.78%-20.89%-38.37% 223B
-0.58%+0.21%+23.55%+56.94% 198B
-1.20%+2.40%+1.14%-32.08% 143B
Average -0.80%+0.85%+24.34%+42.74% 371.78B
Weighted average by Cap. -0.44%+0.16%+33.94%+71.44%

Financials

2026 *2027 *
Net sales 30.46B 26.7B 24.64B 22.69B 42.89B 2,937B 43.56B 295B 115B 1,437B 114B 112B 4,948B 32.38B 28.38B 26.2B 24.12B 45.59B 3,123B 46.31B 313B 123B 1,528B 122B 119B 5,261B
Net income -3.39B -2.97B -2.74B -2.53B -4.77B -327B -4.85B -32.79B -12.86B -160B -12.73B -12.45B -551B 9.76B 8.56B 7.9B 7.27B 13.75B 941B 13.96B 94.4B 37.02B 461B 36.65B 35.85B 1,586B
Net Debt 9.46B 8.29B 7.65B 7.05B 13.32B 912B 13.53B 91.48B 35.87B 446B 35.52B 34.75B 1,537B -
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
26-07-20 $133.21 -0.80% 4,075,894
26-07-17 $134.28 -1.48% 6,903,235
26-07-16 $136.30 +3.49% 7,926,819
26-07-15 $131.70 +1.28% 4,467,637
26-07-14 $130.04 -1.04% 5,255,960
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
134.28USD
Average target price
158.30USD
Spread / Average Target
+17.89%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GILD Stock